Tag: Sanofi

feinstein, northwell

Northwell Health’s Feinstein Institutes Teams Up with Sanofi, Regeneron Pharmaceuticals, Gilead Sciences to Test COVID-19 Treatments

The research arm of Northwell Health (No. 2 on DiversityInc’s 2019 Top Hospitals & Health Systems), the Feinstein Institutes for Medical Research, is partnering with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi (No. 31 on DiversityInc’s 2019 Top 50 Companies for Diversity) to identify treatments for people hospitalized with moderate to severe…

Sanofi’s Commitment to Hematology

Originally published on Sanofi.com. Blood cancers and rare blood disorders account for some of the most challenging diseases to treat, and patients often have limited therapeutic options available to them. Sanofi is committed to significantly improving the health and lives of people with a range of hematologic conditions. Across these…

Patel, preciado, sanofi, ERG

Sanofi’s Chandni Patel and Sodexo’s Jonathan Preciado Discuss How to Drive Business and Organizational Impact Through ERGs

Employee resource groups (ERGs) can be beneficial to businesses beyond improving employee morale and establishing a sense of community. Sodexo (DiversityInc Hall of Famer as No. 1 in 2013 and No. 8 on the 2019 Top Companies for Employee Resource Groups specialty list) director of market research Jonathan Preciado and…

ERG Festival, forum, discussion, DiversityInc

ERG Forum: ERG Festival Participants Feel ‘Inspired,’ ‘Informed’ After Final Session

In the final session of DiversityInc’s 2019 ERG Festival on Nov. 12 at the Newark Liberty International Airport Marriott, Lissiah Hundley, head of strategic partnerships and client fulfillment, led the ERG Forum, where participants had an opportunity to engage in a dialogue. Inspired. Informed. Invigorated. Engaged. Challenged. Supported. Hopeful. Those…

Sanofi: FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

Originally published on Sanofi.com. The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Fluzone® High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two…